Clinical Trial Detail

NCT ID NCT02460224
Title Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Novartis Pharmaceuticals
Indications

kidney cancer

colorectal cancer

melanoma

non-small cell lung carcinoma

Advanced Solid Tumor

stomach cancer

gastroesophageal junction adenocarcinoma

esophagus adenocarcinoma

nasopharynx carcinoma

Therapies

LAG525

PDR001

Age Groups: adult

No variant requirements are available.